Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide Injection Phase IV Study in Dialysis Patients With CKD Anemia Previously Treated With ESAs
CTR20251013Phase 4Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Modality
- PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peglmolesatide in anaemia, chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence of cardiovascular composite safety events. Started May 2025; status: active.
02
Drugs
peglmolesatide
03
Conditions
anaemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20251013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251013.